<DOC>
	<DOCNO>NCT01434186</DOCNO>
	<brief_summary>To evaluate efficacy , safety , tolerability , Saxagliptin ( BMS-477118 ) combination Metformin pediatric patient type 2 diabetes</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-blind , Placebo-controlled Study Evaluate Efficacy Safety Saxagliptin ( BMS-477118 ) Combination With Metformin IR Metformin XR Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control Metformin Alone</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-blind , Placebo-controlled Study Evaluate Efficacy Safety Saxagliptin ( BMS-477118 ) Combination Metformin IR Metformin XR Pediatric Patients Type 2 Diabetes Inadequate Glycemic Control Metformin Alone Combination Baseline Insulin Therapy</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female patient eligible 10 year age , 17 year 30 week age time screen Previously diagnose type 2 diabetes HbA1c ≥7.0 % ≤10.5 % Body weight ≥ 30 kg Stable dose metformin ( ≥ 1000mg ≤ 2000mg ) minimum 2 month Women must negative serum urine pregnancy test Women must breastfeed Current use antidiabetic medication use within specify timeframe prior screen ( Exception : Metformin ) Fasting plasma glucose ( FPG ) &gt; 255 mg/dL Diabetic ketoacidosis ( DKA ) within 6 month study entry Abnormal renal function Active liver disease Anemia An abnormal Thyroid Stimulating Hormone ( TSH ) Creatinine kinase ( CK ) ≥ 3X ULN</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>